Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

$52.68

+0.94 (+1.82%)

(As of 02:48 PM ET)

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
2

Hold
13

Buy
2

Based on 17 Wall Street analysts who have issued ratings for Bristol-Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 2 have given a sell rating, 13 have given a hold rating, and 2 have given a buy rating for BMY.

Consensus Price Target

$55.00
4.40% Upside

According to the 17 analysts' twelve-month price targets for Bristol-Myers Squibb, the average price target is $55.00. The highest price target for BMY is $84.00, while the lowest price target for BMY is $42.00. The average price target represents a forecasted upside of 4.40% from the current price of $52.68.

Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors.

BMY Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	15 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$55.00	$54.67	$60.00	$69.50
Forecasted Upside	4.40% Upside	9.44% Upside	49.78% Upside	20.06% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Get Ready for Next Week’s Elon Musk Shock (Ad)

I believe Elon Musk is about to shock the world again next week… When he’s set to unveil his new AI product. I’m hosting a special online strategy session to help you prepare on Monday at 10am ET.

Click here to see the details and save your seat.

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol-Myers Squibb Stock vs. The Competition

Type	Bristol-Myers Squibb	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	4.40% Upside	810.58% Upside	6.55% Upside
News Sentiment Rating	Positive News See Recent BMY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/23/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Market Perform ➝ Market Perform	$48.00 ➝ $48.00	-3.17%
9/16/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$50.00 ➝ $50.00	+0.70%
8/28/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Hold ➝ Hold	$49.00 ➝ $51.00	+3.91%
8/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$41.00 ➝ $42.00	-11.32%
8/12/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$45.00 ➝ $53.00	+12.15%
7/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$53.00 ➝ $45.00	+5.36%
4/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00	+8.11%
4/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/6/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00	+12.50%
1/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$68.00 ➝ $60.00	+13.67%
11/2/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$68.00 ➝ $54.00	+5.30%
10/30/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $69.00	+35.48%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$56.00 ➝ $50.00	-5.63%
10/27/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$55.00 ➝ $53.00	+0.03%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $60.00	+6.29%
10/6/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$84.00	+47.91%
7/28/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$90.00 ➝ $85.00	+39.89%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$72.00 ➝ $66.00	+5.13%
7/10/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$66.00	+5.35%
4/28/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
10/10/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:12 PM ET.

Should I Buy Bristol-Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 23, 2024. Please send any questions or comments about these Bristol-Myers Squibb pros and cons to contact@marketbeat.com.

Bristol-Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products for various diseases, including hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience.
The company has been actively discovering, developing, and licensing new products, showing a commitment to innovation and growth.
Recent developments in the company's pipeline have shown promising results, indicating potential future revenue growth.
Bristol-Myers Squibb's stock price has been relatively stable and has shown positive trends in recent periods, making it an attractive investment option.
The company has a global presence and a strong distribution network, allowing it to reach a wide market of patients in need of its products.

Bristol-Myers Squibb
Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Bristol-Myers Squibb's future growth prospects.
Market volatility and economic uncertainties may affect the company's stock performance, leading to potential risks for investors.
Recent changes in healthcare policies or regulations could impact Bristol-Myers Squibb's operations and profitability.
The company's success heavily relies on the successful development and commercialization of new products, which may face delays or setbacks in the competitive market.
Investors should carefully consider the potential risks associated with investing in the biopharmaceutical sector, including clinical trial failures and patent expirations.

BMY Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $55.00, with a high forecast of $84.00 and a low forecast of $42.00.
: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
: According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 4.40% based on their 12-month stock forecasts.
: Over the previous 90 days, Bristol-Myers Squibb's stock had 1 downgrade by analysts.
: Bristol-Myers Squibb has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and TD Cowen in the past 90 days.
: Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.